Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor reseptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer

L Gianni, A Llado, G Bianchi, J Cortes, PL Kellokumpu-Lehtinen

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
Pages (from-to)1131-1137
JournalJ Clin Oncol
Issue number7
Publication statusPublished - 2010
Publication typeA1 Journal article-refereed

Cite this